BR112023002724A2 - Neoantígenos ras e seus usos - Google Patents
Neoantígenos ras e seus usosInfo
- Publication number
- BR112023002724A2 BR112023002724A2 BR112023002724A BR112023002724A BR112023002724A2 BR 112023002724 A2 BR112023002724 A2 BR 112023002724A2 BR 112023002724 A BR112023002724 A BR 112023002724A BR 112023002724 A BR112023002724 A BR 112023002724A BR 112023002724 A2 BR112023002724 A2 BR 112023002724A2
- Authority
- BR
- Brazil
- Prior art keywords
- binds
- hla
- allele
- protein encoded
- compositions
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Steroid Compounds (AREA)
Abstract
São descritas composições e métodos para preparar composições de células T e usos das mesmas, incluindo métodos para tratar câncer em um sujeito em necessidade por meio da administração de células T induzidas com peptídeos compreendendo pelo menos um dos epítopos de KRAS com uma sequência GACGVGKSA que se liga a uma proteína codificada por um alelo HLA C03:04; ou tendo uma sequência GAVGVGKSA que se liga a uma proteína codificada por um alelo HLA C03:03 em que a respectiva proteína codificada pelo alelo HLA é expressa em uma célula do sujeito. Também estão incluídas as composições imunogênicas compreendendo peptídeo(s) compreendendo um epítopo descrito acima, ou células apresentadoras de antígeno carregadas com o(s) peptídeo(s) compreendendo o epítopo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063065346P | 2020-08-13 | 2020-08-13 | |
PCT/US2021/045808 WO2022036142A2 (en) | 2020-08-13 | 2021-08-12 | Ras neoantigens and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023002724A2 true BR112023002724A2 (pt) | 2023-05-02 |
Family
ID=80248174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023002724A BR112023002724A2 (pt) | 2020-08-13 | 2021-08-12 | Neoantígenos ras e seus usos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230398218A1 (pt) |
EP (1) | EP4196153A2 (pt) |
JP (1) | JP2023539055A (pt) |
KR (1) | KR20230107206A (pt) |
CN (1) | CN116507354A (pt) |
AU (1) | AU2021325082A1 (pt) |
BR (1) | BR112023002724A2 (pt) |
CA (1) | CA3189269A1 (pt) |
CL (1) | CL2023000426A1 (pt) |
CO (1) | CO2023002959A2 (pt) |
CU (1) | CU20230010A7 (pt) |
IL (1) | IL300565A (pt) |
MX (1) | MX2023001851A (pt) |
WO (1) | WO2022036142A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656788B1 (en) | 1992-08-07 | 2006-10-18 | Pharmexa Inc. | Hla binding peptides and their uses |
DE69435292D1 (de) | 1993-03-05 | 2010-06-17 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
CN110809716B (zh) | 2017-02-12 | 2023-07-07 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
WO2019168984A1 (en) * | 2018-02-27 | 2019-09-06 | Gritstone Oncology, Inc. | Neoantigen identification with pan-allele models |
US20210268091A1 (en) * | 2018-06-19 | 2021-09-02 | Biontech Us Inc. | Neoantigens and uses thereof |
GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
-
2021
- 2021-08-12 EP EP21856745.1A patent/EP4196153A2/en active Pending
- 2021-08-12 IL IL300565A patent/IL300565A/en unknown
- 2021-08-12 MX MX2023001851A patent/MX2023001851A/es unknown
- 2021-08-12 KR KR1020237008657A patent/KR20230107206A/ko unknown
- 2021-08-12 BR BR112023002724A patent/BR112023002724A2/pt unknown
- 2021-08-12 CU CU2023000010A patent/CU20230010A7/es unknown
- 2021-08-12 AU AU2021325082A patent/AU2021325082A1/en active Pending
- 2021-08-12 JP JP2023509798A patent/JP2023539055A/ja active Pending
- 2021-08-12 WO PCT/US2021/045808 patent/WO2022036142A2/en active Application Filing
- 2021-08-12 CN CN202180070306.2A patent/CN116507354A/zh active Pending
- 2021-08-12 CA CA3189269A patent/CA3189269A1/en active Pending
- 2021-08-12 US US18/007,096 patent/US20230398218A1/en active Pending
-
2023
- 2023-02-10 CL CL2023000426A patent/CL2023000426A1/es unknown
- 2023-03-10 CO CONC2023/0002959A patent/CO2023002959A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL300565A (en) | 2023-04-01 |
AU2021325082A1 (en) | 2023-04-20 |
EP4196153A2 (en) | 2023-06-21 |
MX2023001851A (es) | 2023-04-26 |
CA3189269A1 (en) | 2022-02-17 |
US20230398218A1 (en) | 2023-12-14 |
WO2022036142A3 (en) | 2022-03-24 |
KR20230107206A (ko) | 2023-07-14 |
JP2023539055A (ja) | 2023-09-13 |
CL2023000426A1 (es) | 2023-09-08 |
CU20230010A7 (es) | 2023-12-07 |
WO2022036142A2 (en) | 2022-02-17 |
CN116507354A (zh) | 2023-07-28 |
CO2023002959A2 (es) | 2023-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023002724A2 (pt) | Neoantígenos ras e seus usos | |
MacLennan et al. | A human serum immunoglobulin with specificity for certain homologous target cells, which induces target cell damage by normal human lymphocytes | |
BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
BRPI0409879A (pt) | composições e métodos para imunoterapia especìfica wt1 | |
BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
BR112022025806A2 (pt) | Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia | |
BR112021019558A2 (pt) | Composições e métodos para preparar composições de células t e usos dos mesmos | |
BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
BR112022016456A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos | |
BR112014001516A2 (pt) | peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico | |
BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
BR112021022106A2 (pt) | Rna terapêutico para câncer de ovário | |
Maisch | The sarcolemma as antigen in the secondary immunopathogenesis of myopericarditis | |
Woodruff et al. | Synergistic inhibition of mammary carcinoma transplants in A-strain mice by antitumour globulin and C. parvum | |
AR004567A1 (es) | Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi. | |
BR112023022367A2 (pt) | Anticorpos anti-tigit e métodos de uso dos mesmos | |
BR112023017887A2 (pt) | Proteína compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, anticorpo biespecífico, ácido nucleico de codificação do dito primeiro ou segundo polipeptídeo, célula hospedeira, composição farmacêutica, proteína, anticorpo biespecífico ou composição farmacêutica para uso, e, métodos de tratamento e de preparo de um anticorpo biespecífico | |
BR112023024231A2 (pt) | Células t primárias rhd negativas hipoimunogênicas | |
BR112017021016A2 (pt) | preparação de proteína, composição farmacêutica, proteína de fusão, polinucleotídeo isolado, estrutura de ácido nucleico, método para tratamento de doença ou condição associada ao excesso de glutamato, e método de purificação de um polipeptídeo | |
Spengler et al. | Lymphocytotoxic activities of sera from myeloma and other paraproteinemic patients | |
BR112021018684A2 (pt) | Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+ | |
BR112021017486A2 (pt) | Receptores de células t e métodos de uso dos mesmos |